Study | Country Study period Study design |
Data source | Exposure definition | Non-exposure definition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|---|---|---|---|---|---|---|---|
Gold 2015 |
Worldwilde Until June 2014 retrospective cohort |
Clinical development program of dimethyl fumarate (DMF). | Pregnancies exposed to dimethyl fumarate (DMF). |
unexposed, sick
Pregnancies exposed to placebo. |
during pregnancy (anytime or not specified) | 42 / 13 | Only data related to clinical trials was used in this meta-analysis, in order to have a control group. | |
Clinical studies with administration of DMF. The study treatment was discontinued immediately in the event of pregnancy. | ||||||||
Nguyen (control exposed to IFN) 2019 |
International 2005 - 2016 prospective cohort |
The Multiple Sclerosis (MS) Base Registry is a large, international observational cohort study, with long-term prospectively collected data. | Pregnancies occurring during dimethyl fumarate therapy. (This is a subgroup of exposure among the exposed group considered in the study). |
exposed to other treatment, sick
Pregnancies occurring during Interferon beta (all) therapy. (This is a subgroup of exposure among the exposed group considered in the study). |
during pregnancy (anytime or not specified) | 17 / 350 | ||
Data in the MSBase registry, including prospective pregnancy data, is entered in real time or near real time, as part of routine clinical visits. Information collected included: disease-modifying therapies exposure before and during pregnancy. | ||||||||
Nguyen (control unexposed, sick) 2019 |
International 2005 - 2016 prospective cohort |
The Multiple Sclerosis (MS) Base Registry is a large, international observational cohort study, with long-term prospectively collected data. | Pregnancies occurring during dimethyl fumarate therapy. (This is a subgroup of exposure among the exposed group considered in the study). |
unexposed, sick
Pregnancies not exposed to disease-modifying therapies (DMTs) (pregnancy occurring within a year of DMT discontinuation or without DMT exposure in the prior year). |
during pregnancy (anytime or not specified) | 17 / 886 | ||
Data in the MSBase registry, including prospective pregnancy data, is entered in real time or near real time, as part of routine clinical visits. Information collected included: disease-modifying therapies exposure before and during pregnancy. |
Study | Country Study period Study design |
Data source | Case | Control | Exposition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|
Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;